Case Report

Idiopathic Adult Onset Fanconi's Syndrome in a Patient Treated with Oxaliplatin

Nguyen A and Benz S*

Department of Medicine, Medical College of Wisconsin, USA

*Corresponding author: Samantha Benz, Department of Medicine, Medical College of Wisconsin, Wauwatosa, Wisconsin, USA

Received: April 09, 2021; Accepted: April 26, 2021;

Published: May 03, 2021

Abstract

Proximal tubular injury is known complication of chemotherapy such as carboplatin. However, there are far more other causes of injury and in many situations, the etiology is difficult to elucidate. Here we describe a case of a patient who presented with a urine analysis consistent of Fanconi's syndrome with signs and symptoms of the disorder prior to chemotherapy but requiring admission for aggressive electrolyte replacement soon after the chemotherapy was completed. We further discuss causes of Fanconi's syndrome and the importance of evaluation of the proximal convoluted tubule prior to administration of chemotherapy.

Keywords: FOLFOX; Fanconi's syndrome

Introduction

Fanconi's syndrome is a rare disease that is characterized by wasting of glucose and electrolytes that are typically reabsorbed by the proximal convoluted tubule of the nephron. Since this portion of the nephron is so active in reabsorption of electrolytes, it is also prone to damage when its metabolic demands are not met. Here we describe a case of a man with a likely preexisting Fanconi's syndrome who developed profound glucose and electrolyte wasting after receiving FOLFOX which is typically not associated with development of Fanconi's syndrome.

Case

Pt is a 78-year-old male with a past medical history of stage IV colon cancer. Patient presented with a chief complaint of near syncope. Pt has found to have a urinalysis significant for >1000 mg/dl of glucose, and 100 mg/dl of protein. Blood studies were significant for hypoalbuminemia at 1.7 g/dL, and normal electrolytes with a potassium of 3.5 mmol/L, sodium of 132 mmol/L, magnesium of 2.3 mg/dL, and phosphorus of 1.3 mg/dL. Urine electrolytes were notable for an elevated potassium of 69.2 mmol/L and sodium of 52 mmol/L. Microalbumin was elevated at 22.0 mg/dL. The total protein was 2549 mg/24H. Fractionated proteins in the urine resulted with albumin 17.90 mg/dL, Alpha-1 globulin 16.30 mg/dL, alpha-2 globulin 20.82 mg/dL, beta globulin 24.68 mg/dL, gamma globulin 14.51 mg/dL, the total random urine protein was elevated at 2035 mg/24hour. Free kappa light chain was elevated at 25.00 mg/dL, free lambda light chain was 16.97 mg/L, with a Kappa/Lambda ratio of 1.47. Patient's glucose was 500 on a urine analysis four years prior.

Pt was negative for lead and had no history which caused us to suspect venom or other rarer causes of Fanconi's syndrome. Patient completed one cycle of FOLFOX approximately one week prior to hospitalization with oxaliplatin. History was evaluated extensively for causes of Fanconi's syndrome and was negative for lead poisoning, animal bites, or topic medications.

Treatment

Electrolytes were aggressively replaced.

Outcome and Follow up

Repeat urine studies continued to show increased glucose in the urine. Patient did not recover function of his proximal convoluted tubule. Urine analysis continued to show glucose in the urine.

Discussion

Adult-acquired Fanconi syndrome is a rare condition generalized by wasting of amino acids, glucose, phosphate, uric acid and various ions from the proximal renal tubule. The diagnosis of Fanconi syndrome could be made by the following findings of aminoaciduria, hypophosphatemia and findings of renal tubular acidosis (type 2) [1]. The pathophysiology of Fanconi syndrome lies in the defect in the proximal convoluted tubule whereby the reabsorption capacity of the kidney becomes reduced. As a result, abnormalities such as amino acid, glucose, phosphate, and bicarbonate are found in the urine within this patient group.

While most cases of adult onset Fanconi's syndrome is typically associated with monoclonal gammopathy, in our case there was no evidence of monoclonal gammopathy [2]. It is unlikely that in our case the oxaliplatin given to the patient caused the proximal tubular damage on top of a developing Fanconi's syndrome, as the glucose in the patient's urine was elevated prior to the first cycle of FOLFOX. Further, our patient still has evidence of Fanconi's syndrome a month after treatment. It is increasingly important for evaluation and planning in regard to the number of checks needed for a patient in post chemo follow-up.

Other causes of Fanconi syndrome features disruptions to mitochondrial functioning as the primary mechanism. In a paper by Klootwijk et al. an EHHADH gene was identified that encodes for a peroxisomal enzyme [3]. When this encoded enzyme is mutated, it mistargets mitochondria, instead of peroxisomes, leading to disruption of fatty acid oxidation and an energy production. This disruption causes mitochondrial damage and leakage of metabolites consistent with a phenotype of Fanconi Syndrome. Another common cause of Fanconi syndrome is by drug induction. The most common culprits of drug-induced Fanconi Syndrome includes valproic acid,

aminoglycosides, and cisplatin. Numerous of studies have found a link between these medications with mitochondrial toxicity and the manifestation of the Fanconi phenotype [4]. Overall, while the exact underlying mechanism for Fanconi Syndrome has not been elucidated, the mitochondria play an integral role in generating the ATP necessary for active transport in the proximal convoluted tubule. Disruption to these essential organelles have been shown in both the drug-induced and hereditary models to lead to a biochemical presentation consistent with Fanconi Syndrome [4]. The astute clinician should be well aware of the possibility of a co-occurring idiopathic Fanconi's Syndrome and the necessity of close monitoring to prevent fatal arrhythmias.

Learning Points

- Underlying Fanconi's syndrome should be evaluated prior to patient's receiving chemotherapy.
- It is possible that chemotherapy which is not known to cause Fanconi's may push a pre-damaged kidney into a Fanconi's syndrome. Clinicians should be diligent in this evaluation.

References

1. Karatzas A, Paridi D, Kozyrakis D, Tzortzis V, Samarinas, M, Dailiana Z, et al. Fanconi syndrome in the adulthood. The role of early diagnosis and treatment. *Journal of musculoskeletal & neuronal interactions*. 2017; 17: 303-306.
2. Messiaen T, Deret S, Mougenot B, Bridoux F, Dequiedt P, et al. Adult Fanconi Syndrome secondary to light Chain Gammopathy: Clinicopathologic heterogeneity and unusual features in 11 patients. *Medicine*. 2000; 79: 135-154.
3. Klotwijk ED, Reichold M, Helip-Wooley A, Tolaymat A, Broeker C, Robinette SL, et al. Mistargeting of Peroxisomal α -hydroxyacid oxidase and Inherited renal Fanconi's Syndrome. *New England Journal of Medicine*. 2014; 370: 129-138.
4. Heidari R, Jafari F, Khodaei F, Yeganeh BS, Niknahad H. Mechanism of valproic acid-induced Fanconi syndrome INVOLVES mitochondrial dysfunction and oxidative stress in rat kidney. *Nephrology*. 2018; 23: 351-361.